reports
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi ...
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Company’s mission of health equity. In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his “vision to make healthcare more affordable and accessible” and the impact that Tevogen Bio has had on the world. Tevogen’s business ...
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 7...
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased 24% compared to the reported amount on March 31, 2025; ...
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Heal...
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company”) (Nasdaq: ), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an unrelenting passi...
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in F...
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50...
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial...
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWI...
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235. The Warren Township P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contributes to the D.A.R.E. and Explorer programs, prov...
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that Founder and CEO of Tevogen, Dr. Ryan Saadi, donated 10,000 of his personal shares of common stock to the Opportunity Project, a Millburn, N.J.–based nonprofit dedicated to empowering individuals with brain injuries through its innovative Clubhouse model. Founded in 1993, Opportunity Project has served more than 600 individuals and their families, providing programs that foster independence, self‑es...
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fu...
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company”) (Nasdaq: ), today issued the following statement from Ryan Saadi, M.D., M.P.H., Founder and CEO. “Tevogen is an asset-rich enterprise, and we plan on sharing a comprehensive inventory of Tevogen’s wholly owned internally developed assets and their standard methodology valuation. These intangible assets are not reflected in financial reports due to US GAAP accounting rules, but they do underscore the magnitude of what we have b...
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsof...
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Ho...
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value E...
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), reiterates investor confidence and estimated asset value over $10 billion. In October 2024, HMP Partners and The Patel Family LLP, investors in innovative healthcare ventures, congratulated Tevogen Bio and Dr. Ryan Saadi for their efforts to alleviate health inequality through breakthrough life-saving medical innovations. Hema Patel, Managing Partner of HMP Partners and The Patel Family LLP, remarked, “We are i...
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast...
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion over the first five years. WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmod...
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion i...
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success through patient accessibility. WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech dev...
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI E...
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. ...
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% ...
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on March 31, 2025, institutional ownership of Tevogen common stock increased by 60% compared to the reported amount on December 31, 2024. The largest contributors t...
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Re...
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), today announced it has received the $1 million in funding to adva...
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holder...
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions WARREN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on March 31, 2025, institutional ownership of Tevogen common stock increased by 60% compared to the reported amount on December 31, 2024. The largest contributors to this ...
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Buil...
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams. WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings In...
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion ...
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically impactful, economically accessible therapies by leveraging cutting-edge science and technology. Te...
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expan...
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative.The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC. WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (“Tevogen” or the “Company) (Nasdaq: ), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program. The funding would be provided un...
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission. Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep conviction in Tevogen’s miss...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.